tetano
Editor, Senior Moderator
Blood Adv
. 2021 Sep 28;5(18):3690-3693.
doi: 10.1182/bloodadvances.2021004977.
Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection
Lauren E Merz[SUP] 1 [/SUP], Kavita Mistry[SUP] 1 [/SUP], Donna Neuberg[SUP] 2 [/SUP], Revital Freedman[SUP] 3 [/SUP], Gerda Menard[SUP] 4 [/SUP], David M Dorfman[SUP] 4 [/SUP], Hae Soo Park[SUP] 3 [/SUP], Katherine Jolley[SUP] 3 [/SUP], Maureen O Achebe[SUP] 3 5 [/SUP]
Affiliations
Abstract
The COVID-19 pandemic has highlighted racial health disparities within the United States. Although social determinants of health are the most likely drivers of this disparity, it is possible that genetic traits enriched in the black population like sickle cell trait (SCT) could worsen the morbidity and mortality of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients admitted for SARS-CoV-2 infection who identified as black or African American were included in the study (n = 166). Blood remnants were tested for SCT, and clinical data were abstracted from the chart. There was no difference in mortality between those with SCT and those without. There was no difference in respiratory complications between groups, but those without SCT had a much higher burden of chronic lung disease (P = .004). Those with SCT had higher creatinine on admission (P = .004), but no difference in in-hospital renal complications (P = .532). Notably, 12% of the cohort had SCT, which is higher than the expected 7.31% (P = .025). Our study did not show any evidence of increased end organ damage, morbidity, or mortality from SARS-CoV-2 infection among patients with SCT but did show differences in admission creatinine and preexisting lung disease.
. 2021 Sep 28;5(18):3690-3693.
doi: 10.1182/bloodadvances.2021004977.
Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection
Lauren E Merz[SUP] 1 [/SUP], Kavita Mistry[SUP] 1 [/SUP], Donna Neuberg[SUP] 2 [/SUP], Revital Freedman[SUP] 3 [/SUP], Gerda Menard[SUP] 4 [/SUP], David M Dorfman[SUP] 4 [/SUP], Hae Soo Park[SUP] 3 [/SUP], Katherine Jolley[SUP] 3 [/SUP], Maureen O Achebe[SUP] 3 5 [/SUP]
Affiliations
- PMID: 34581772
- DOI: 10.1182/bloodadvances.2021004977
Abstract
The COVID-19 pandemic has highlighted racial health disparities within the United States. Although social determinants of health are the most likely drivers of this disparity, it is possible that genetic traits enriched in the black population like sickle cell trait (SCT) could worsen the morbidity and mortality of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients admitted for SARS-CoV-2 infection who identified as black or African American were included in the study (n = 166). Blood remnants were tested for SCT, and clinical data were abstracted from the chart. There was no difference in mortality between those with SCT and those without. There was no difference in respiratory complications between groups, but those without SCT had a much higher burden of chronic lung disease (P = .004). Those with SCT had higher creatinine on admission (P = .004), but no difference in in-hospital renal complications (P = .532). Notably, 12% of the cohort had SCT, which is higher than the expected 7.31% (P = .025). Our study did not show any evidence of increased end organ damage, morbidity, or mortality from SARS-CoV-2 infection among patients with SCT but did show differences in admission creatinine and preexisting lung disease.